MANAGEMENT TEAM

The Drais management team is made up of highly experienced individuals who have demonstrated abilities in pharmaceutical development, registration, manufacturing and commercialization. All have proven track records with leading pharmaceutical companies and as a team a successful entrepreneurial history. The team brings to Drais a broad, in-depth knowledge of drug development over a wide range of therapeutic areas.

Donna L. Tempel, Ph.D., President and CEO

Dr. Tempel is a co-founder of Drais, Inc. and prior to the founding of Drais; Dr. Tempel was Chief Operating Officer of AkaRx, Inc. responsible for overseeing the clinical development of AkaRx’s treatment for thrombocytopenia (AKR-501). Dr. Tempel was Vice President, Project Management at Yamanouchi Pharma America and was responsible for overseeing the conduct of all clinical development programs including those for Vesicare® and Vaprisol®. At Yamanouchi Dr. Tempel was responsible for building the Project Management organization globally and for implementing Project Management principles and practices. Prior to joining Yamanouchi, Dr. Tempel has held various positions in Clinical Research and Development at Bristol Myers Squibb and Johnson and Johnson.

Dr. Tempel received a B.S. degree in Psychology and Mathematics from Hunter College, CUNY, doctorate in Neurological Sciences from CUNY/Mount Sinai School of Medicine and an M.B.A. from Farleigh Dickinson University.

Robert E. Desjardins, M.D., Chief Scientific Officer

Dr. Desjardins is a co-founder of Drais, Inc. and prior to the founding of Drais, Dr. Desjardins was President and CEO of AkaRx, Inc. Dr. Desjardins was Chief Development Officer, Euro-America for Yamanouchi Group Business Ltd. He was responsible for building the clinical development capabilities of Yamanouchi Pharmaceuticals in the U.S. and for the clinical development of Vesicare® and Vaprisol®. Dr. Desjardins was Vice President of World Wide Clinical Research at Lederle Pharmaceuticals and Head of Anti-Infective Clinical Research at Burroughs Wellcome. He was a member of the Anti-malarial Drug Development Program at the Walter Reed Army Institute of Research in Washington DC, a collaboration that resulted in the development of the anti-malarial drugs mefloquine and halofantrine. Dr. Desjardins has been awarded grants from the World Health Organization and the U.S. Army Medical Research Division and was an Adjunct Professor in the Center of Drug Development Science at Georgetown University. In 2005 he was awarded the Gary Neil Prize for Innovation in Drug Development by the American Society of Clinical Pharmacology and Therapeutics.

Dr. Desjardins received his medical degree from Loyola University in Chicago.

Rudolph W. Lucek, Executive Vice President, Regulatory Affairs and Quality Assurance

Prior to joining Drais, Mr. Lucek was a co-founder and Executive Vice President of Regulatory Affairs and Quality Assurance at AkaRx, Inc. Mr. Lucek was Vice President of Regulatory Affairs at Yamanouchi Pharma America and was responsible for creating and managing the regulatory affairs department for Yamanouchi in the U.S. During his 5 years with Yamanouchi, Mr. Lucek directed the filing and approval of two successful electronic New Drug Applications for Vesicare® and Vaprisol®, and until the merger of Yamanouchi and Fujisawa in 2005; he oversaw all regulatory aspects of the launch and commercialization of Vesicare® and Vaprisol®. Mr. Lucek had a long career with Hoffmann La Roche where he held positions on the Department of Drug Metabolism, Department of Pharmacokinetics and Biopharmaceutics and was Director of International Regulatory Affairs, Group Director of Marketed Products and Group Director of Regulatory Intelligence.

Mr. Lucek holds a B.S. in Chemistry from Lafayette College, M.S. in Biochemistry from Seton Hall University, and M.B.A. from Rutgers University, and is a member of the National Business School Honor Society, Beta Gamma Sigma.

Steven M. Silbert, Executive Vice President, Operations

Prior to joining Drais, Mr. Silbert was a co-founder and Executive Vice President of Operations at AkaRx, Inc. Mr Silbert was Senior Director, Clinical Administration and Quality Assurance at Yamanouchi Pharma America overseeing clinical operations for the development of Vesicare® and Vaprisol®. Before joining Yamanouchi, Mr. Silbert held positions of Director, Clinical Operations and Director, Worldwide Quality Assurance at Pharmaceutical Research Associates (PRA) and was Director, Global Clinical Quality Assurance with Lederle Laboratories. He is an experienced clinical development manager with in-depth experience in clinical operations, quality assurance and clinical administration with a 30 year track record in successfully structuring and developing organizations and implementing clinical programs.

Mr. Silbert holds a B.A. degree in biology from Guilford College and an M.S. in tropical medicine and parasitology from Columbia University, School of Public Health and Administrative Medicine.